Sex Hormone-Binding Globulin and Cholesterol

Pharmacotherapeutic group: S01BD01 - Class III antiarrhythmic drugs. The main pharmaco-therapeutic action: the antiarrhythmic action and has a moderate blocking effect on ?-adrenoreceptors, decreases the maximum rate of depolarization and action potential amplitude in purkinje fibers do not affect the resting potential, the most pronounced effect is registered in the system Hissa-purkinje; demonstrate the efficiency of organic heart lesions, Sublingual patients who have suffered MI. Pharmacotherapeutic group: S07AV09 - selective antagonists of ?-blockers. obstructive lung disease, myasthenia gravis, hypersensitivity to medication, severe hepatic failure. Side effects and complications in the use of drugs: asymptomatic hypotension, symptomatic hypotension (diaphoresis, dizziness), violations of peripheral blood circulation, pallor, flush to Traction face, bradycardia (heart rate below 50 beats / min) chest pain, syncope, pulmonary edema and AV-block, bradycardia / sinus pause / asystole, dizziness, drowsiness, confusion, headache, psychomotor agitation, feelings of fatigue, paresthesia, asthenia, depression, violation thinking, anxiety, anorexia, convulsions, respiratory - bronchospasm, difficulty breathing, shortness of breath, nasal hyperemia, wheezing, gastrointestinal tract - nausea, vomiting, dyspepsia, constipation, dry mouth transitional adjustment discomfort in the abdomen, breach of taste feelings; adverse reactions at the injection site, including inflammation and consolidation, swelling, redness or color change skin burning sensation at the injection site, thrombophlebitis and local skin necrosis with extravasation, urinary retention, speech disorders, vision, pain in the area mizhlopatkovyy, chills and fever, in perioperative period - bradycardia and bronchospasm. Contraindications to the use of drugs: hypersensitivity to the drug; AV block II - III degree, cardiogenic shock, expressed hypotension, severe heart failure, sinus weakness, liver and kidney disease, pregnancy, lactation, infancy. Method of production of drugs: Table., Coated tablets, 150 mg, 300 mg. The main pharmaco-therapeutic effects: anti arrhythmic effect, extending the third phase of action potential of cardiac cells is mainly due to slow flow in the potassium channel, causing bradykardychnyy effect by lowering sinus automatism, such action is not antagonistic to atropine, a noncompetitive ?-and ?-anti-adrenergic effect, slows conduction in the SA-node, atrial and AV-node, which is more pronounced when accelerating rhythm, intraventricular conduction does not change, increases refractory period and reduces the excitability of atrial myocardium, AV-node and ventricular levels, slows conduction and Anti-nuclear Antibody refractory period in additional AV-tract myocardium reduces oxygen consumption by moderate decrease peripheral resistance and decrease heart rate, increases transitional adjustment blood flow by a direct Streptokinase on smooth muscle artery infarction and supports cardiac output by reducing the pressure and peripheral resistance, without revealing any negative inotropic effects transitional adjustment . Dosing and Administration of drugs: SUPRAVENTRICULAR tahiarytmiya - dosage should be chosen individually by titration in which each step contains a loading dose and subsequent dose supportive, always loading dose of 500 mg / kg (0.05 ml / kg at concentrations of 10 mg / ml), which is introduced for 1 min, supporting effective dose drug for the treatment SUPRAVENTRICULAR transitional adjustment is 50-200 mg / kg / min, although used and such high doses, 300 mg / kg / min.; for a small number of patients sufficient dose is 25 mg / kg / min; scheme beginning of treatment and maintenance therapy - Loading dose Heart Rate 500 mg / kg / min for 1 min, then maintenance dose 50 mg / kg / min for 4 min, with a positive result - maintenance dose 50 mg Right Lower Lobe-lung kg / min., with negative results within 5 minutes - repeat administration with dosages of 500 mg / kg / min for 1 min to improve the supportive dosage to 100 mg / kg / min for 4 min, a positive result - maintenance dose of 100 ug / kg / min., with negative results within 5 minutes - repeat administration with dosages of 500 mg / kg / min for 1 min; sustaining dose increase to 150 mg / kg / min for 4 min, a positive result: the introduction of a maintenance dose of 150 mg / kg / min., with negative results - repeat administration with dosages of 500 mg / kg / min for 1 min to improve the supportive dose to 200 mg / kg / min and keep at that level, while achieving the desired degree of reduction in heart rate or ceiling security to stop the introduction of loading dose and dosing interval to reduce the base maintenance of the introduction of the 50 mg / kg / min to 25 mg / kg / min or even lower, if necessary, the interval between titration steps can be increased from transitional adjustment to 10 minutes, with emergence of adverse events can reduce dose or stop the introduction, pharmacological adverse reactions should stopped for 30 minutes.